Although, our studies demonstrate significant drug synergy in vitro, failing to replicate it in vivo using multiple KRAS-mutated CRC cell lines and PDXs highlight the importance of careful in vivo validation studies in preclinical settings. The gene discussed is KRAS; the disease is colorectal carcinoma.